![Andreas Seidl](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Andreas Seidl
Technik-/Wissenschafts-/F&E-Leiter bei
FORMYCON AG
Profil
Andreas Seidl currently works at Formycon AG, as Chief Scientific Officer from 2022.
Dr. Seidl also formerly worked at LEUKOCARE AG, as Chief Operating Officer from 2019 to 2022, Hexal Biotech GmbH, as Head-Analytics & Quality Control from 2002 to 2010, and Novartis AG, as Site Manager from 2010 to 2015.
Dr. Seidl received his doctorate degree from Universität Konstanz.
Aktive Positionen von Andreas Seidl
| Unternehmen | Position | Beginn |
|---|---|---|
| FORMYCON AG | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2022 |
Ehemalige bekannte Positionen von Andreas Seidl
| Unternehmen | Position | Ende |
|---|---|---|
LEUKOCARE AG
 LEUKOCARE AG Medical/Nursing ServicesHealth Services Develops protein stabilization and protection solutions | Geschäftsführer | 01.01.2022 |
| NOVARTIS AG | Corporate Officer/Principal | 01.01.2015 |
Ausbildung von Andreas Seidl
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
52
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Universität Konstanz
 Universität Konstanz Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LEUKOCARE AG
LEUKOCARE AG Medical/Nursing ServicesHealth Services Develops protein stabilization and protection solutions | Health Services |
Formycon AG
 Formycon AG Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
